Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 12
Large cardiovascular outcomes study, SOUL, to be initiated
mid 2018 with OZEMPIC
SOUL study design
~13,000
patients on
standard
of care¹
OzempicⓇ 1.0 mg sc QW
Placebo
Study purpose and end-points
• Purpose: To confirm that treatment with OzempicⓇ results
in decreased cardiovascular risk compared to placebo
Study design: Randomised and double-blinded
Primary endpoint: Cardiovascular death, non-fatal
myocardial infarction or non-fatal stroke (MACE)
Around 3.5-5 years
• Results: SOUL study results expected in 2023
1 Inclusion criteria: Type 2 diabetes, established cardiovascular disease or cardiovascular kidney disease,
HbA1c 6.5%-10%
sc: Subcutaneous; QW: Once-weekly
changing
diabetes®
MACE: Major adverse cardiovascular event
novo nordiskView entire presentation